ESMO Living Guideline on Oncogene-Addicted Metastatic NSCLC

European Society for Medical Oncology (ESMO) shared a post on LinkedIn:

”The new ESMO Living Guideline on Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer is now online. Updated treatment algorithms and recommendations, directly linked to ESMO-MCBS scores and references, easily accessible on desktop and mobile devices.

Prepared by Lizza Hendriks, Francesco Cortiula, Elene Mariamidze, Diogo Martins Branco, George Pentheroudakis and Martin Reck.”

Source: European Society for Medical Oncology/LinkedIn

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.